Product Description
St. Jude Children's Research Hospital is developing sarcolysin as an anticancer medicine. It is a type of chemotherapy that works by slowing or stopping growth of cancer cells. It may be used to help prepare patients for hematopoietic cell transplant. (Sourced from: https://together.stjude.org/en-us/diagnosis-treatment/medicines-list/melphalan.html)
Mechanisms of Action: Alkylating Agent
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: India | Russia
Approved Indications: None
Known Adverse Events: None
Company: City of Hope Medical Center
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Neuroblastoma|Acute Myeloid Leukemia|Acute Lymphoid Leukemia|Ganglioneuroblastoma|Preleukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myelodysplastic Syndrome
Phase 2: Anemia, Aplastic|Preleukemia|Lymphoma|Chronic Myeloid Leukemia|Lymphoma, Non-Hodgkin|Graft vs Host Disease|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Leukemia|Multiple Myeloma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myelodysplastic Syndrome|Juvenile Myelomonocytic Leukemia,|Acute Monocytic Leukemia|Chronic Lymphoid Leukemia|Paroxysmal Hemoglobinuria|Acute Myelomonocytic Leukemia|Chronic Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Sarcoma, Myeloid|Adult T-Cell Leukemia-Lymphoma|Neuroblastoma|T-Cell Lymphoma|Plasmablastic Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Large-Cell Immunoblastic Lymphoma|Myelofibrosis|Thrombocythemia, Essential|Polycythemia Vera|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Mantle-Cell Lymphoma|Hodgkin Lymphoma|Burkitt Lymphoma|Anemia, Refractory, with Excess of Blasts|Follicular Lymphoma|Crohn Disease|Thrombocytosis|Lymphoma, B-Cell|Biphenotypic Acute Leukemia|Histiocytosis, Langerhans-Cell|HIV Infections|Myeloid, Accelerated Leukemia|Prolymphocytic B-Cell Leukemia|Leukemia, Plasma Cell|Prolymphocytic Leukemia|Waldenstrom Macroglobulinemia|Prolymphocytic T-Cell Leukemia|Myelodysplastic-Myeloproliferative Diseases|Blast Crisis|B-Cell Leukemia|Myeloproliferative Disorders|Melanoma
Phase 1: Myelogenous, Chronic, BCR-ABL Positive Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Myelomonocytic Leukemia|Chronic Lymphoid Leukemia|Sarcoma, Ewing|Myeloproliferative Disorders|Acute Monocytic Leukemia|Chronic Myeloid Leukemia|Myelodysplastic Syndrome|Anemia, Aplastic|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell|Blast Crisis|Acute Lymphoid Leukemia|Multiple Myeloma|Acute Myeloid Leukemia|Lymphoma, Non-Hodgkin|Chronic Myelomonocytic Leukemia|Preleukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Juvenile Myelomonocytic Leukemia,|Neuroblastoma|Lymphoma|Rhabdoid Tumor|Wilms Tumor|Renal Cell Carcinoma|Myeloid, Accelerated Leukemia|Melanoma|Clear Cell Sarcoma|Biphenotypic Acute Leukemia|Gastrointestinal Cancer|Rhabdomyosarcoma|Adenomyoepithelioma|Clear Cell Adenocarcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
---|---|---|---|---|---|---|---|
21D.466 | P2 |
Recruiting |
Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Acute Monocytic Leukemia|Lymphoma, Non-Hodgkin|Acute Myeloid Leukemia|Myelofibrosis|Polycythemia Vera|Multiple Myeloma|Thrombocytosis|Anemia, Aplastic|Adult T-Cell Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Acute Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Juvenile Myelomonocytic Leukemia,|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myelodysplastic Syndrome|Thrombocythemia, Essential |
2032-04-01 |
2025-05-16 |
||
NCI-2023-08530 | P3 |
Recruiting |
Ganglioneuroblastoma |
2029-12-31 |
2024-11-27 |
Primary Endpoints|Treatments |
|
MYELOMATCH | P2 |
Recruiting |
Myelodysplastic Syndrome|Acute Myeloid Leukemia |
2029-05-15 |
2025-05-03 |
||
2006-7041-83/hah | N/A |
Not yet recruiting |
Chronic Cough |
2023-10-31 |
|||
NCI-2016-00584 | P2 |
Recruiting |
Multiple Myeloma|Biphenotypic Acute Leukemia|Chronic Lymphoid Leukemia|Preleukemia|Acute Myelomonocytic Leukemia|Anemia, Refractory, with Excess of Blasts|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Acute Monocytic Leukemia|Lymphoma, B-Cell|Leukemia, Plasma Cell|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Juvenile Myelomonocytic Leukemia,|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Myelodysplastic Syndrome|Myelodysplastic-Myeloproliferative Diseases|Chronic Myelomonocytic Leukemia|Myeloproliferative Disorders|B-Cell Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Lymphoid Leukemia|Myeloid, Accelerated Leukemia|Lymphoma, Non-Hodgkin |
2027-05-31 |
2025-05-10 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
ASCT2031 | P3 |
Active, not recruiting |
Acute Lymphoid Leukemia|Myelodysplastic Syndrome|Preleukemia|Acute Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma |
2026-06-30 |
2025-05-06 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
PRO11090340 | P2 |
Recruiting |
Crohn Disease |
2025-12-01 |
2019-08-21 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCI-2016-01915 | P1 |
Completed |
Acute Lymphoid Leukemia|Lymphoma, B-Cell|Acute Myeloid Leukemia|Preleukemia|Myelodysplastic Syndrome|Lymphocytic Chronic B-Cell Leukemia|Blast Crisis|Lymphoma, Non-Hodgkin|Anemia, Aplastic|Leukemia, Plasma Cell|Acute Monocytic Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Multiple Myeloma|Acute Myelomonocytic Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Juvenile Myelomonocytic Leukemia,|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Chronic Myelomonocytic Leukemia|Chronic Lymphoid Leukemia|Myeloproliferative Disorders|Chronic Myeloid Leukemia |
2023-02-13 |
2023-02-18 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
0669-19-FB | P2 |
Terminated |
Multiple Myeloma |
2022-12-21 |
2023-08-30 |
Primary Endpoints|Start Date|Treatments |
|
NCI-2018-01236 | P2 |
Completed |
Preleukemia|Acute Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Juvenile Myelomonocytic Leukemia,|Chronic Myeloid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Monocytic Leukemia|Myelodysplastic Syndrome|Hodgkin Lymphoma|Histiocytosis, Langerhans-Cell|Chronic Myelomonocytic Leukemia|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Myeloid, Accelerated Leukemia|Acute Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Anemia, Refractory, with Excess of Blasts|Biphenotypic Acute Leukemia |
2022-09-20 |
2023-06-30 |
Primary Endpoints |
|
NCI-2013-02183 | P2 |
Completed |
Preleukemia|Blast Crisis|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myelodysplastic Syndrome|Myeloid, Accelerated Leukemia |
2022-02-28 |
2024-01-18 |
||
NCI-2012-02071 | P1 |
Unknown status |
Preleukemia|Lymphocytic Chronic B-Cell Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Biphenotypic Acute Leukemia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Multiple Myeloma|Chronic Myeloid Leukemia|Acute Lymphoid Leukemia|Myeloid, Accelerated Leukemia|Lymphoma, Non-Hodgkin|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Leukemia, Plasma Cell|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Chronic Lymphoid Leukemia|Lymphoma, B-Cell |
2021-11-01 |
2022-02-02 |
Primary Endpoints|Treatments|Trial Status |
|
Neuroblastoma Protocol 2012 | P2 |
Active, not recruiting |
Neuroblastoma |
2021-10-21 |
2024-11-27 |
Primary Endpoints|Treatments |
|
HAPNK1 | P2 |
Completed |
Lymphoma|Leukemia |
2021-08-27 |
2022-11-01 |
Patient Enrollment|Primary Endpoints|Treatments |
|
AMC-097 | P2 |
Active, not recruiting |
Large-Cell Immunoblastic Lymphoma|Lymphoma, Non-Hodgkin|Plasmablastic Lymphoma|T-Cell Lymphoma|Follicular Lymphoma|Mantle-Cell Lymphoma|Burkitt Lymphoma|HIV Infections |
2021-05-13 |
2024-11-27 |
Primary Endpoints|Treatments |
|
OSU-19190 | P2 |
Terminated |
Multiple Myeloma |
2021-05-08 |
2023-09-29 |
Primary Endpoints |
|
NCI-2016-00477 | P2 |
Completed |
Anemia, Refractory, with Excess of Blasts|Myelodysplastic Syndrome|Acute Monocytic Leukemia|Chronic Myelomonocytic Leukemia|Chronic Myeloid Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Preleukemia |
2020-03-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
RADIANT | P1 |
Completed |
Renal Cell Carcinoma|Neuroblastoma|Gastrointestinal Cancer|Rhabdomyosarcoma|Clear Cell Adenocarcinoma|Lymphoma|Rhabdoid Tumor|Melanoma|Wilms Tumor|Clear Cell Sarcoma|Sarcoma, Ewing|Adenomyoepithelioma |
2020-02-10 |
2020-10-20 |
Primary Endpoints |
|
NCI-2012-03168 | N/A |
Withdrawn |
Immunoblastic Lymphadenopathy|Sezary Syndrome|Lymphomatoid Granulomatosis|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Hairy Cell Leukemia|Burkitt Lymphoma|AIDS-Related Lymphoma|Leukemia, Plasma Cell|Adult T-Cell Leukemia-Lymphoma|Large-Cell Immunoblastic Lymphoma|Lymphoma, Non-Hodgkin|Follicular Lymphoma|B-Cell Marginal Zone Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Mycosis Fungoides|Extranodal NK-T-Cell Lymphoma|Waldenstrom Macroglobulinemia|T-Cell Peripheral Lymphoma|Diffuse Large B-Cell Lymphoma|Large-Cell Anaplastic Lymphoma|Large Granular Lymphocytic Leukemia|Mantle-Cell Lymphoma|Plasmablastic Lymphoma|T-Cell Cutaneous Lymphoma|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Intraocular Lymphoma |
2019-02-01 |
2024-11-27 |
Primary Endpoints |
|
NCI-2009-01334 | P2 |
Completed |
Prolymphocytic T-Cell Leukemia|T-Cell Lymphoma|Prolymphocytic B-Cell Leukemia|Waldenstrom Macroglobulinemia|Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Leukemia, Plasma Cell|Prolymphocytic Leukemia|Multiple Myeloma|Lymphoma, Non-Hodgkin|Chronic Lymphoid Leukemia |
2018-06-30 |
2024-11-27 |
Primary Endpoints |
|
ASCIST | P1 |
Completed |
Lymphoma|Neuroblastoma |
2017-12-20 |
2024-11-27 |
Primary Endpoints |
|
Ewing/Allo | P1 |
Completed |
Sarcoma, Ewing |
2016-12-01 |
2019-03-20 |
Treatments |
|
11-X335 | P2 |
Withdrawn |
Melanoma |
2016-02-01 |
2024-06-26 |
Primary Endpoints |
|
REFNK1 | P2 |
Terminated |
Juvenile Myelomonocytic Leukemia,|Lymphoma, Non-Hodgkin|Sarcoma, Myeloid|Preleukemia|Myelodysplastic Syndrome|Chronic Myeloid Leukemia|Chronic Myelomonocytic Leukemia|Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Acute Monocytic Leukemia|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Myelomonocytic Leukemia |
2015-04-01 |
2019-03-20 |
||
ANBL0532 | P3 |
Completed |
Neuroblastoma |
2015-02-27 |
2024-11-27 |
Primary Endpoints |